Cytotoxic Drugs Market Size, Share, and Trends 2024 to 2034

Cytotoxic Drugs Market Size and Companies

The global cytotoxic drugs market size was USD 16.28 billion in 2023, calculated at USD 17.16 billion in 2024 and is expected to reach around USD 28.99 billion by 2034, expanding at a CAGR of 5.4% from 2024 to 2034. The growing prevalence of the cancer that fueling the growth of the market.

Cytotoxic Drugs Market Key Takeaways

• North America led the market with the largest market share of 39% in 2023.
• Asia Pacific is expected to witness the fastest growth in the market during the forecast period.
• By type, the branded drugs segment has held the biggest market share of 67% in 2023.
• By type, the generic drugs segment is expected to witness significant growth during the forecast period.
• By drug class, the antimetabolites segment has recorded more than 51% of market share in 2023.
• By routes of administration, the oral segment led the market with the largest market share of 63% in 2023.
• By application, the oncology segment has held more than 82% of market share in 2023.
• By distribution channel, the hospital pharmacies segment held a significant share of the market in 2023.

U.S. Cytotoxic Drugs Market Size and Growth 2024 to 2034

The U.S. cytotoxic drugs market size reached USD 4.44 billion in 2023 and is expected to be worth around USD 8.10 billion by 2033 at a CAGR of 5.60% from 2024 to 2034.

North America led the cytotoxic drugs market in 2023. The region is expected to sustain its growth during the forecast period. The well-developed healthcare infrastructure and the increasing adoption of technological advancements in healthcare and diagnostic equipment are boosting the growth of the market.

The rising disposable income of the people and the rising investment in healthcare by individuals in regional countries like the United States and Canada are further propelling the growth of the market. The rising research and development in the advancement of cancer drugs and treatment to offer better outcomes are driving the expansion of the cytotoxic drugs market across the region.

Asia Pacific is expected to witness the fastest growth in the cytotoxic drugs market during the forecast period. The rising geriatric population and shift in lifestyle, rising consumption of alcohol and smoking, causing higher cases of cancer in the region. The government is highly investing in creating awareness about the prevention and treatment of cancer, and the increasing development of research centers, hospitals, and diagnostics centers is driving the expansion of the market across the region.

• In April 2024, Sanofi, a leading French pharma, is launching the best-selling drug from its pipeline in India. The pharma giant is setting a plan to reconstruct its strategies in India and claiming that it is still an un-presented market.

Market Overview

The global cytotoxic drugs market is highly attributed to the rising prevalence of cancer cases worldwide due to the changing lifestyle and geriatric population. Cytotoxic drugs are the treatment of cancer in the procedure of chemotherapy that acts in the cancer cells. The cytotoxic drug is given to patients who are suffering from the abnormal expansion of cells in the body. Cancer cells, bone marrow, hair follicles, and cells in the intestine and stomach are some of the types of rapid cell expansion.

Chemotherapy is one of the types of cytotoxic medications that can kill all the rapidly growing cells. This type of procedure is a combination of drugs, and the cycle of the procedure is repeated. Thus, the rising number of cancer patients worldwide are other chronic diseases that are driving the growth of the cytotoxic drugs market.

Cytotoxic Drugs Market Growth Factors

• The rising prevalence of chronic diseases such as cancer is driving the demand for an effective treatment that can treat the disease, driving the growth of the market.
• The aging population, environmental solutions, changing lifestyle preferences, and accepting sedentary lifestyles like higher consumption of alcohol and smoking causing severe diseases fueling the demand for effective treatments that drive the growth of the market.
• The rising advancements in cancer medication and supporting government policies for making cancer treatment affordable and available in every region of the country are driving the growth of the cytotoxic drugs market.
• The rising awareness regarding cancer treatment and medication, such as chemotherapy, and the rising number of chemotherapy procedures due to the increasing number of cancer patients globally drive the expansion of the market.
• The rising investments in research and development activities in the innovation of new drugs and treatments are boosting the growth of the cytotoxic drugs market.

Cytotoxic Drugs Market Scope

Market Dynamics

Driver

Rising cases of cancer

The increasing prevalence of cancer patients, along with other chronic diseases, is driving the growth of the cytotoxic drugs market. The rising urbanization, increasing pollution levels due to higher industrialization, accepting a sedentary lifestyle, and rising consumption of alcohol and smoking are causing higher chances of cancer.

Cancer is the abnormal and rapid growth of cells in the body that cause severe harm to the body. The increasing cases of cancer are contributing to the higher demand for effective treatment procedures like chemotherapy. Thus, the rising number of chemotherapy procedures is driving the demand for the cytotoxic drugs market.

Restraint

Side effects of medications

The side effects associated with the cytotoxic drug on normal cells are limiting the adoption of the drug in the market. Chemotherapy is considered the most important part of cancer treatment because it does not differentiate the affected cells from the normal cells, which results in harming the normal cells and causes several side effects in the body. Thus, it is restraining the growth of the cytotoxic drugs market.

Opportunity

The rising awareness about the treatment

The increasing awareness about cancer treatment, early diagnosis, and prevention treatment are boosting the growth of the market. The favorable government support in affording the treatment for cancer by providing various insurance and other policies and organizing the awareness campaign for creating and educating the people for the prevention and diagnosis of the diseases that are fueling the expansion of the market. Additionally, the rising investments in research and development activities by pharmaceutical companies for innovating new drugs and treatments for the treatment of cancer are driving the opportunity for the growth of the cytotoxic drugs market.

Type Insights

The branded drugs segment dominated the cytotoxic drugs market in 2023 and will continue doing so throughout the forecast period. The demand for branded drugs is owing to their reliability, market exclusiveness, and patent-protected properties. A branded drug is also known as an innovator drug, and it is the first available in the market. Branded drugs are manufactured by the pharmaceutical company that has held the patent for over 20 years. In branded drugs and generic drugs, the active components of the active components are the same, but the inactive components, like preservatives and dyes, may change. Patent protection of the drug allows it to regain its investments in research and development activities, drug development, maintenance, and control of the price, and it helps generate revenue before the entrance of generic medicines.

The generic drugs segment is expected to witness significant growth during the forecast period. The higher adoption of generic drugs due to their cost convenience is driving the expansion of the segment. Generic drugs are the type of medication that is subsidized in terms of cost by the government, and it does not require any R&D due to their exact components similar to branded drugs. Thus, affordability and effectiveness contribute to the growth of the generic drug market.

Drug Class Insights

The antimetabolites segment was estimated to account for the largest part of the cytotoxic drugs market in 2023. The higher adoption of antimetabolites in chemotherapy for the treatment of cancers ranging from breast cancer and cervical cancer to colorectal cancer and blood cancer. Antimetabolites work on the rapidly dividing cells and help chemotherapeutic agents gain the fast-growing tumor cells. The antimetabolites are used to disrupt the nuclei pathways used in various autoimmune and rheumatological conditions like rheumatoid arthritis and multiple sclerosis.

Pharmaceutical companies are increasingly investing in research and development activities to enhance effectiveness. Adrucil, 5-FU (5-fluorouracil), Alimta (pemetrexed), Cytosar U, Ara-C (cytarabine), Droxia, Hydrea, Siklos (hydroxyurea), Fludara (fludarabine), Gemzar (gemcitabine), Otrexup, Rasuvo, Trexall, Xatmep (methotrexate), Purinethol, 6-MP (6-mercaptopurine), Xeloda (capecitabine) these are some of the common types of antimetabolites used in the cancer treatment.

Routes of Administration Insights

The oral segment dominated the cytotoxic drugs market in 2023. The higher oral administration of cytotoxic drugs by patients suffering from cancer provides the better convenience and comfort of self-administration of drugs in their home. Oral cytotoxic drugs are a patient-friendly and less invasive option of treatment and can be taken into the home comfort. Patients prefer oral administration of cytotoxic drugs over intravenous catheter placement.

The oral administration of the cytotoxic drug reduced the frequent visits to hospitals or diagnosis centers. Additionally, the higher availability of oral cytotoxic drugs and the increasing investments in research and development activities in the formulation and innovations in oral cytotoxic drugs enhance the growth of the segment.

Applications Insights

The oncology segment dominated the cytotoxic drugs market in 2023. Oncology is the treatment or medication associated with the treatment, diagnosis, and prevention of early-stage cancer. The rising research and development activities in the several fields of oncology, from cancer cell biology to optimal palliative care and pain relief and chemotherapy treatment regimens, help enhance the efficiency of oncology treatment.

There are some of the tools associated with oncology diagnosis are biopsy for the removal of tumor tissues that can be examined under the microscope, endoscopy for the gastrointestinal tract, CT scanning, imaging studies like X-rays, ultrasound, and other radiological techniques, MRI scanning, Scintigraphy, Positron emission tomography Single Photon Emission computed tomography, nuclear medicine techniques, and others.

Distribution Channel Insights

The hospital pharmacies segment held a significant share of the cytotoxic drugs market in 2023. The growth of hospital pharmacies is attributed to the higher availability of cancer care services, in-time access, and the provision of supporting professionals and medication for patients who are undergoing cancer treatment. Hospitals are well-equipped with trained professionals, diagnostic equipment, and medication like cytotoxic drugs that are demanded for treating any type of cancer at any stage. Hospitals have trained professionals and pharmacists who are experts in sterile compounding techniques and drug management that help provide accurate and safe cytotoxic medication as per the requirements of the cancer patient.

Cytotoxic Drugs Market Companies

• CytoPharma
• Bristol-Myers Squibb
• Amgen Inc.
• Celgene Corp.
• Eli Lilly and Company

Cytotoxic Drugs Market Recent Developments

• In April 2024, SaniSure, a leading player in single-use bioprocessing products, launched the Fill4Sure, a single-use custom filling assembly manufactured to influence drug to the market and make efficiency, security, and repeatability in the drug product filling.
• In April 2024, Ipsen S.A., a leading pharmaceutical company focusing on rare diseases, oncology, and neuroscience with a portfolio of commercial drug products, announced the collaboration with Sutro Biopharma, Inc. for the development of a pre-clinical antibody drug candidate.
• In April 2024, Tevogen Bio Holdings (Tevogen), a specialist in clinical clinical-stage immunotherapy biotech company, developed genetically unmodified T-cell therapeutics in oncology, virology, and neurology.
• In April 2024, a clinical-stage biopharmaceutical organization, Corvus Pharmaceuticals, Inc., announced its double-blind, randomized, placebo-controlled Phase 1 clinical trial for identifying soquelitinib in patients with moderate to severe atopic dermatitis.

Segments Covered in the Report

By Type

• Branded Drug
• Generic Drug

By Drug Class

• Antimetabolites
• Alkylating Agents
• Cytotoxic Antibiotics
• Vinca Alkaloids and Etoposide
• Antineoplastic Drugs

By Routes of Administration

• Oral
• Parenteral

By Applications

• Oncology
• Rheumatoid Arthritis
• Multiple Sclerosis

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa